Navigation Links
ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
Date:4/16/2013

Cleveland, OH (PRWEB) April 16, 2013

Determining the drug-induced inhibition of the cardiac hERG potassium channel is recommended by both the International Conference on Harmonization (ICH) and the US Food and Drug Administration (FDA) in order to predict delayed cardiac repolarization (DR) and cardiac risk. However, extending this determination to actually identifying drugs that may cause TdP, a serious polymorphic ventricular tachycardia, has been challenging.

In response to this need, ChanTest has introduced the CardioChannelGram™ - cardiac ion channel profiling plus logistic regression models that predict DR and TdP risk. Predictivity is significantly better when quantitative drug effects on Cav1.2 and Nav1.5 ion channels, in addition to hERG, are measured. Cardiac risk can now be characterized earlier in development than ever before using automated patch clamp platforms.

“ChanTest is pleased to be responding to the industry's needs by introducing this new line of testing to the drug discovery community,” said Arthur "Buzz" Brown, Ph.D., M.D., CEO, President and founder. “Our new CardioChannelGram™ and SaVety Assessment will provide greater insight into potential cardiac risk, allowing more effective decision-making in early preclinical development.”

Click here to learn more about the ChanTest CardioChannelGram™ and SaVety Assessment.

FURTHER INFORMATION
ChanTest
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:

Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines, and nonclinical cardiac risk assessment service portfolio, is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past several years. ChanTest is based in Cleveland, Ohio.

Visit http://www.chantest.com to learn more about what we do.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10634495.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
2. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
3. Diagenode Introduces Innovative Bioruptor® Pico for Micro-Volume Chromatin and DNA Shearing
4. Texas Fertility Center Introduces Oncofertility Education Program for Physicians and Patients
5. Finesse Solutions Introduces SmartParts for Intelligent Universal Controllers
6. Cearna Introduces Product Designed to Reduce Patient’s Recovery Time From Facial Plastic Surgery
7. Rigaku Introduces New Instruments at Pittcon 2013
8. GIN Introduces Advanced Robotics and Dispensing Technology at BVS La Jolla Biotech Day
9. FMC BioPolymer Introduces Its New Portfolio of Nature-Based Nutritional Solutions
10. Percival Scientific, Inc. Introduces an Affordable LED Lighting System for the Research Industry
11. Palomar Medical Center in San Diego County Introduces New Wrist-Worn Wireless Patient Vital Signs Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... ... 14, 2017 , ... Opal Kelly, a leading producer of ... announced the release of SYZYGY™, a new open standard for connecting high-performance peripherals ... compact, low cost, low pin-count, high-performance connectivity solution between FPGAs and single-purpose hardware ...
(Date:8/11/2017)... Calif. (PRWEB) , ... August 11, 2017 , ... Algenist ... plant collagen-based formulation unlocking collagen like never before. , Collagen is the key ... firsts to market with Liquid Collagen™, which include: , ...
(Date:8/10/2017)... , ... August 09, 2017 , ... ... medicine applications in the clinic is here. The team at Capricor Therapeutics, Inc. ... conditioned medium for clinical studies. , Dr. Travis Antes, head of analytical ...
(Date:8/10/2017)... (PRWEB) , ... August 10, 2017 , ... DrugDev ... new educational webinar to demonstrate how Good Clinical Practice (GCP) can be ... documents. In addition the webinar will discuss the importance of GCP compliance, how sites ...
Breaking Biology Technology:
(Date:6/23/2017)... and ITHACA, N.Y. , June ... Cornell University, a leader in dairy research, today announced ... designed to help reduce the chances that the global ... onset of this dairy project, Cornell University has become ... Sequencing the Food Supply Chain, a food safety initiative ...
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
Breaking Biology News(10 mins):